HomeComparePIRS vs EPRT

PIRS vs EPRT: Dividend Comparison 2026

PIRS yields 14.71% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $10.9K in total portfolio value· pulled ahead in Year 9
10 years
PIRS
PIRS
● Live price
14.71%
Share price
$13.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52.5K
Annual income
$3,650.55
Full PIRS calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — PIRS vs EPRT

📍 EPRT pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPIRSEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PIRS + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PIRS pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PIRS
Annual income on $10K today (after 15% tax)
$1,250.00/yr
After 10yr DRIP, annual income (after tax)
$3,102.97/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $7,811.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PIRS + EPRT for your $10,000?

PIRS: 50%EPRT: 50%
100% EPRT50/50100% PIRS
Portfolio after 10yr
$57.9K
Annual income
$8,245.63/yr
Blended yield
14.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

PIRS
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-1.7
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PIRS buys
0
EPRT buys
0
No recent congressional trades found for PIRS or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPIRSEPRT
Forward yield14.71%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$52.5K$63.4K
Annual income after 10y$3,650.55$12,840.73
Total dividends collected$25.1K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: PIRS vs EPRT ($10,000, DRIP)

YearPIRS PortfolioPIRS Income/yrEPRT PortfolioEPRT Income/yrGap
1$12,171$1,470.59$11,205$505.18+$966.00PIRS
2$14,695$1,672.70$12,672$682.46+$2.0KPIRS
3$17,611$1,887.56$14,490$930.48+$3.1KPIRS
4$20,958$2,114.15$16,786$1,282.69+$4.2KPIRS
5$24,777$2,351.33$19,753$1,791.56+$5.0KPIRS
6$29,109$2,597.87$23,677$2,541.64+$5.4KPIRS
7$33,999$2,852.44$29,008$3,672.99+$5.0KPIRS
8$39,493$3,113.67$36,463$5,425.08+$3.0KPIRS
9← crossover$45,637$3,380.17$47,238$8,221.57$1.6KEPRT
10$52,483$3,650.55$63,385$12,840.73$10.9KEPRT

PIRS vs EPRT: Complete Analysis 2026

PIRSStock

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Full PIRS Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this PIRS vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PIRS vs SCHDPIRS vs JEPIPIRS vs OPIRS vs KOPIRS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.